OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Dick C. Chan, Gerald F. Watts
Current Opinion in Lipidology (2024) Vol. 35, Iss. 3, pp. 101-109
Closed Access | Times Cited: 9
Dick C. Chan, Gerald F. Watts
Current Opinion in Lipidology (2024) Vol. 35, Iss. 3, pp. 101-109
Closed Access | Times Cited: 9
Showing 9 citing articles:
Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies
Anand Athavale, Eri Fukaya, Nicholas J. Leeper
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 6, pp. 1165-1170
Closed Access | Times Cited: 7
Anand Athavale, Eri Fukaya, Nicholas J. Leeper
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 6, pp. 1165-1170
Closed Access | Times Cited: 7
What is the phenotype of heterozygous lipoprotein lipase deficiency?
Robert A. Hegele
Current Opinion in Lipidology (2025)
Closed Access
Robert A. Hegele
Current Opinion in Lipidology (2025)
Closed Access
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Jakub Michał Zimodro, Manfredi Rizzo, Ioanna Gouni‐Berthold
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 147-147
Open Access
Jakub Michał Zimodro, Manfredi Rizzo, Ioanna Gouni‐Berthold
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 147-147
Open Access
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Maud Ahmad, Robert A. Hegele
Molecular Diagnosis & Therapy (2025)
Open Access
Maud Ahmad, Robert A. Hegele
Molecular Diagnosis & Therapy (2025)
Open Access
Advances in Pathological Mechanisms and Comprehensive Management of Hyperlipidemic Pancreatitis
柠 罗
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1975-1983
Closed Access
柠 罗
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 1975-1983
Closed Access
Shooting the Messenger to Treat Hypertriglyceridemia
Gerald F. Watts
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1818-1823
Closed Access | Times Cited: 3
Gerald F. Watts
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1818-1823
Closed Access | Times Cited: 3
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Timo Strandberg, Petri T. Kovanen, Donald M. Lloyd‐Jones, et al.
The Lancet (2024)
Closed Access | Times Cited: 2
Timo Strandberg, Petri T. Kovanen, Donald M. Lloyd‐Jones, et al.
The Lancet (2024)
Closed Access | Times Cited: 2
Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?
Gerald F. Watts, Dick C. Chan
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 10, pp. 1224-1226
Open Access | Times Cited: 1
Gerald F. Watts, Dick C. Chan
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 10, pp. 1224-1226
Open Access | Times Cited: 1
Hipertrigliceridemias graves: lo necesario y lo suficiente
José Luis Díaz-Díaz
Clínica e Investigación en Arteriosclerosis (2024)
Open Access
José Luis Díaz-Díaz
Clínica e Investigación en Arteriosclerosis (2024)
Open Access
